112 related articles for article (PubMed ID: 34858809)
1. First Line and Second Line Chemotherapy in Advanced Cholangiocarcinoma and Impact of Dose Reduction of Chemotherapy: A Retrospective Analysis.
Möhring C; Feder J; Mohr RU; Sadeghlar F; Bartels A; Mahn R; Zhou T; Marinova M; Feldmann G; Brossart P; von Websky M; Matthaei H; Manekeller S; Glowka T; Kalff JC; Weismüller TJ; Strassburg CP; Gonzalez-Carmona MA
Front Oncol; 2021; 11():717397. PubMed ID: 34858809
[TBL] [Abstract][Full Text] [Related]
2. Impact of regular additional endobiliary radiofrequency ablation on survival of patients with advanced extrahepatic cholangiocarcinoma under systemic chemotherapy.
Gonzalez-Carmona MA; Möhring C; Mahn R; Zhou T; Bartels A; Sadeghlar F; Bolch M; Vogt A; Kaczmarek DJ; Heling DJ; Dold L; Nattermann J; Branchi V; Matthaei H; Manekeller S; Kalff JC; Strassburg CP; Mohr RU; Weismüller TJ
Sci Rep; 2022 Jan; 12(1):1011. PubMed ID: 35046437
[TBL] [Abstract][Full Text] [Related]
3. A Real-World Data Study to Evaluate Treatment Patterns, Clinical Characteristics and Survival Outcomes for First- and Second-Line Treatment in Locally Advanced and Metastatic Urothelial Cancer Patients in Germany.
Niegisch G; Gerullis H; Lin SW; Pavlova J; Gondos A; Rudolph A; Haas G; Hennies N; Kramer MW
J Cancer; 2018; 9(8):1337-1348. PubMed ID: 29721042
[No Abstract] [Full Text] [Related]
4. Second-line systemic treatment for advanced cholangiocarcinoma.
Rogers JE; Law L; Nguyen VD; Qiao W; Javle MM; Kaseb A; Shroff RT
J Gastrointest Oncol; 2014 Dec; 5(6):408-13. PubMed ID: 25436118
[TBL] [Abstract][Full Text] [Related]
5. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen.
Sendur MA; Ozdemir N; Özatlı T; Yazıcı O; Aksoy S; Ekinci AS; Yazılıtaş D; Günaydın Y; Oksuzoglu B; Benekli M; Zengin N
Med Oncol; 2014 Sep; 31(9):153. PubMed ID: 25099765
[TBL] [Abstract][Full Text] [Related]
6. Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer.
Neuzillet C; Casadei-Gardini A; Brieau B; Vivaldi C; Brandi G; Tougeron D; Filippi R; Vienot A; Silvestris N; Pointet AL; Lonardi S; Rousseau B; Scartozzi M; Dahan L; Aprile G; Le Sourd S; Evesque L; Meurisse A; Lièvre A; Vernerey D; ;
Int J Cancer; 2020 Dec; 147(11):3177-3188. PubMed ID: 32525595
[TBL] [Abstract][Full Text] [Related]
7. Real-World Effectiveness of Chemotherapy in Elderly Patients With Metastatic Bladder Cancer in the United States.
Galsky MD; Pal SK; Lin SW; Ogale S; Zivkovic M; Simpson J; Derleth C; Schiff C; Sonpavde G
Bladder Cancer; 2018 Apr; 4(2):227-238. PubMed ID: 29732393
[TBL] [Abstract][Full Text] [Related]
8. Long term responders to palliative chemotherapy for advanced biliary tract cancer.
Doherty MK; McNamara MG; Aneja P; McInerney E; Moignard S; Horgan AM; Jiang H; Panzarella T; Jang R; Dhani N; Hedley D; Knox JJ
J Gastrointest Oncol; 2017 Apr; 8(2):352-360. PubMed ID: 28480074
[TBL] [Abstract][Full Text] [Related]
9. Time to progression after first-line tyrosine kinase inhibitor predicts survival in patients with metastatic renal cell carcinoma receiving second-line molecular-targeted therapy.
Ishihara H; Kondo T; Yoshida K; Omae K; Takagi T; Iizuka J; Tanabe K
Urol Oncol; 2017 Sep; 35(9):542.e1-542.e9. PubMed ID: 28619633
[TBL] [Abstract][Full Text] [Related]
10. Multi-institutional retrospective analysis of FOLFIRI in patients with advanced biliary tract cancers.
Mizrahi JD; Gunchick V; Mody K; Xiao L; Surapaneni P; Shroff RT; Sahai V
World J Gastrointest Oncol; 2020 Jan; 12(1):83-91. PubMed ID: 31966916
[TBL] [Abstract][Full Text] [Related]
11. A Population-Based Retrospective Study of Biliary Tract Cancers in Alberta, Canada.
Beaulieu C; Lui A; Yusuf D; Abdelaziz Z; Randolph B; Batuyong E; Ghosh S; Bathe OF; Tam V; Spratlin JL
Curr Oncol; 2021 Jan; 28(1):417-427. PubMed ID: 33450805
[No Abstract] [Full Text] [Related]
12. A phase 2 and biomarker study of cabozantinib in patients with advanced cholangiocarcinoma.
Goyal L; Zheng H; Yurgelun MB; Abrams TA; Allen JN; Cleary JM; Knowles M; Regan E; Reardon A; Khachatryan A; Jain RK; Nardi V; Borger DR; Duda DG; Zhu AX
Cancer; 2017 Jun; 123(11):1979-1988. PubMed ID: 28192597
[TBL] [Abstract][Full Text] [Related]
13. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma.
Kobayashi S; Terashima T; Shiba S; Yoshida Y; Yamada I; Iwadou S; Horiguchi S; Takahashi H; Suzuki E; Moriguchi M; Tsuji K; Otsuka T; Asagi A; Kojima Y; Takada R; Morizane C; Mizuno N; Ikeda M; Ueno M; Furuse J
Cancer Sci; 2018 Aug; 109(8):2549-2557. PubMed ID: 29856900
[TBL] [Abstract][Full Text] [Related]
14. Optimal chemotherapy treatment for women with recurrent ovarian cancer.
Fung-Kee-Fung M; Oliver T; Elit L; Oza A; Hirte HW; Bryson P
Curr Oncol; 2007 Oct; 14(5):195-208. PubMed ID: 17938703
[TBL] [Abstract][Full Text] [Related]
15. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
16. Gemcitabine and capecitabine for advanced biliary cancer.
Gabriel E; Gandhi S; Attwood K; Kuvshinoff B; Hochwald S; Iyer R
J Gastrointest Oncol; 2017 Aug; 8(4):728-736. PubMed ID: 28890824
[TBL] [Abstract][Full Text] [Related]
17. Combination versus mono-therapy as salvage treatment for advanced biliary tract cancer: A comprehensive meta-analysis of published data.
Ying J; Chen J
Crit Rev Oncol Hematol; 2019 Jul; 139():134-142. PubMed ID: 30979533
[TBL] [Abstract][Full Text] [Related]
18. Chemotherapy for cholangiocarcinoma: An update.
Ramírez-Merino N; Aix SP; Cortés-Funes H
World J Gastrointest Oncol; 2013 Jul; 5(7):171-6. PubMed ID: 23919111
[TBL] [Abstract][Full Text] [Related]
19. Second-line chemotherapy in advanced biliary cancers: A retrospective, multicenter analysis of outcomes.
Lowery MA; Goff LW; Keenan BP; Jordan E; Wang R; Bocobo AG; Chou JF; O'Reilly EM; Harding JJ; Kemeny N; Capanu M; Griffin AC; McGuire J; Venook AP; Abou-Alfa GK; Kelley RK
Cancer; 2019 Dec; 125(24):4426-4434. PubMed ID: 31454426
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and Safety of Apatinib Treatment for Advanced Cholangiocarcinoma After Failed Gemcitabine-Based Chemotherapy: An Open-Label Phase II Prospective Study.
Zhang G; Gong S; Pang L; Hou L; He W
Front Oncol; 2021; 11():659217. PubMed ID: 34012920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]